Leadership

Seasoned executive with in-Depth experience in finance and accounting

SEC compliance and corporate governance

Former CFO of EntreMed, Inc., New Generation Biofuels, Inc., and RegeneRx Biopharmaceuticals, Inc.

Most recently CFO with Seneca Biopharma Inc., which merged with Leading Biosciences Inc., in April 2021

B.S. Business Administration – University of Maryland

Bill Hirschman is an accomplished Sales & Marketing leader in the Life Sciences industry who brings over forty years of experience to BullFrog AI. Over his career he has delivered a consistent track record of exceeding sales and revenue targets across diverse industries for both large and small companies. Having spent his career in the Life Sciences industry Bill has gained “hands-on” practice with clinical laboratory testing, immunochemistry, molecular diagnostics and 20 years of CRO and clinical supplies experience. He is skilled at creating strategies and implementing go-to-market plans from idea stage into action. He led multiple business turnarounds, including two multinational companies exceeding 500% growth and $1B in revenue.

Prior to joining BullFrog AI, Bill was Vice President, Sales & Marketing for Societal CDMO (formerly Recro Pharma). Other commercial leadership experience include: Worldwide Clinical Trials, Thermo Fisher Scientific, Covance and Baxter Healthcare Corporation. Bill has a BA Communications Arts & Science from Michigan State University.

30+ years experience in Information Technology for Business

Founder, Delmarva Group LLC

Director of IT Architecture for Day and Zimmerman, Inc

Over 20 years of industry experience in R&D and business development

Most recently served as Senior VP of R&D at Seneca Biopharma, overseeing development of the company’s stem cell-based therapeutics platform

9 granted US patents and multiple foreign patents in stem cells and regenerative medicine

BA – Kalamazoo College

PhD, Genetics – University of Illinois College of Medicine

Assistant Professor of Medicine, Psychiatry, and Pharmacology – Johns Hopkins University, School of Medicine

Research is focused on neuropsychiatric drug development with a precision medicine approach to the treatment of mental illness

B.S. Premedicine, Pennsylvania State University

Ph.D. Clinical Pharmaceutical Sciences, Univ. of Pittsburgh

Neuralstem/ Seneca Biosciences Corporation, Germantown, Maryland – Chief Medical Officer

Vericel Corporation, Cambridge, Massachusetts – Chief Medical Officer

Takeda Global Research and Development, Deerfield, Illinois

Senior Vice President, Clinical Sciences

Vice President, Clinical Sciences

University of Michigan Medical School – Ann Arbor, Michigan

M.D. with Distinction, University of Michigan – Ann Arbor, Michigan

Former Technology Transfer Manager – National Cancer Institute/NIH

B.S. Molecular Biology, Towson University

B.S. Chemistry, Towson University

Ph.D., Molecular Medicine, University of Maryland School of Medicine

Chief Business Officer with Aspect Biosystems, Inc.

Global Strategic Alliances Leader, Cell & Gene Therapy – ThermoFisher Scientific, Life Science Solutions Group

30+ years in the development of biopharmaceuticals, cell therapy and tissue engineered products

Authored 9 patents in drug delivery, biomaterials, cell therapy & tissue engineering

B.Sc. in Biochemistry, McGill University

Former VP/GM – Diagnostics and Cell & Gene Therapy – ThermoFisher Scientific; oversaw a $200+ million business & a fully-integrated 400+ person staff

Director of Revenue Strategy & Operations for the Corporate Executive Board -Johnson & Johnson

B.S. Chemical Engineering, MIT

B.S. Economics, MIT

MBA, Northwestern University Kellogg School of Management

Research interests leverage synthetic genomics technologies that lead to the creation of a synthetic organism based on Mycoplasma mycoides subspecies capri to better study and develop therapeutics for human and animal diseases.

Current projects include the development of vaccines and therapeutics for human and animal viral diseases as well as phage therapeutics targeted against AMR organisms.

Ph.D. in Biochemistry from the University of Texas at Austin

Postdoctoral fellow at Johns Hopkins University-School of Medicine

Master’s degree in Chemistry from Western Illinois University

Bachelor’s degree in Biochemistry from the University of Illinois at Urbana-Champaign